Tanzania registers life-saving drug for postpartum hemorrhage
By Amy Grossman - Communications Manager
The Tanzanian Food and Drug Authority officially announced September 27, 2007 it has approved the registration of misoprostol for controlling postpartum hemorrhage (PPH), the life-threatening bleeding after childbirth attributed to the loss of approximately 5,250 mother's lives annually in Tanzania.
For over a year and a half, our non-profit organization Venture Strategies for Health and Development, working in collaboration with UC Berkeley's School of Public Health, has helped Tanzania obtain regulatory approval of misoprostol for controlling postpartum hemorrhage, the top cause of maternal death worldwide. The Tanzanian's registration of misoprostol for PPH is only the second in Africa after Nigeria who, with VSHD assistance, obtained the world's first regulatory approval of misoprostol for PPH in January of 2006.
Plans for misoprostol's country-wide marketing and dissemination are in progress. Integral to that strategy will be reaching the rural, poor women who stand to benefit the most by the drug's availability. The Tanzanian Government’s announcement is a positive step toward enabling traditional birth attendants to continue to provide a safer birthing environment with misoprostol for the rural women they serve.
Project Reports on GlobalGiving are posted directly to globalgiving.org by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.
If you donate to this project or have donated to this project, you will get an e-mail when this project posts a report. You can also subscribe for reports via e-mail without donating or by subscribing to this project's RSS feed.
Get Reports via Email
We'll only email you new reports and updates about this project.